Apocrine acne, otherwise known as hidradenitis suppurativa, is a chronic inflammatory scarring disease affecting the apocrine gland-bearing skin. We present a case of a 34-year-old woman with severe vulval apocrine acne who was successfully treated initially with prednisolone and then maintained on long-term isotretinoin. This case indicates that long-term treatment with isotretinoin may be more successful than the usual 4-6 months treatment regime.
A 34-year-old woman presented 8 weeks post partum with such severe and painful vulval inflammation that she was unable to walk or sleep. Vulval 'boils' had begun 2 years previously during her second pregnancy. Despite numerous courses of antibiotics and topical treatments including potassium permanganate soaks, metronidazole 0.75% gel (metrogel), mupirocin 2% ointment (bactroban) and various antiseptics, the problem had persisted. There was a past history of scarring acne, quiescent for the last 6 years.
Examination revealed multiple pustular and cystic lesions located on swollen red labia majora (Fig. 1) . A few cystic lesions were noted in both axillae and behind the ears. A diagnosis of apocrine acne (hidradenitis suppurativa) was made. In view of the intense discomfort and difficulty in walking the patient was admitted to hospital.
Full blood count and glucose were normal. The erythrocyte sedimentation rate (20 mm/h) and C-reactive protein (18 mg/L) were raised. Swabs from the vulval lesions grew a mixture of diphtheroids, Proteus, lactose fermenting coliform, Streptococcus faecalis and coagulasenegative Staphylococcus. No Streptococcus milleri were found. 1 A biopsy taken from a purulent lesion on the labia majora showed two densely inflamed hair follicles bridged by aggregates of neutrophils forming microabscesses. Immunofluorescence was negative, as were tissue bacterial and fungal cultures. Our current regime for the management of violently purulent cystic acne (acne fulminans and pyoderma faciale) comprises pretreatment with oral steroids and anti-inflammatory antibiotics, followed by the gradual introduction of isotretinoin and later the cautious withdrawal of steroids. We embarked on this same course with our patient and Fig. 2 illustrates diagramatically the gratifying response. Prednisolone 20 mg per day and erythromycin 500 mg four times per day were commenced. After four weeks the prednisolone was gradually reduced; 10 mg/day for 7 weeks, 5 mg/day for 12 weeks and 2.5 mg/day for 4 weeks. The erythromycin was also tailed off after 4 weeks to 500 mg/day for a further 8 weeks. Isotretinoin 20 mg/day (0.33 mg/kg/day) was introduced after 8 weeks of prednisolone and erythromycin. After 4 weeks this was increased to 40 mg/day (0.66 mg/kg/day) and further increased to 60 mg/day (0.98 mg/kg/day). This was continued for 12 months and by the end of this period the vulva was clear of inflammation. However, 1 month after discontinuation of the isotretinoin one or two cystic lesions erupted on the labia majora and therefore isotretinoin 60 mg/day was restarted and continued for a further 3 months. No significant relapse of the vulval apocrine acne has occurred during the last 10 months after finally discontinuing the isotretinoin.
Hidradenitis suppurativa is a chronic, indolent condition characterized by purulent inflammation in apocrine glands 2 and is thus better called apocrine acne. Lesions form in the apocrine gland-bearing skin of the axillae, the anogenital area, the areolae and behind the ears. The disease rarely begins before puberty when apocrine gland activity is minimal. 3 Bridged comedones are the hallmark, and multiple abscesses may develop frequently progressing to form sinus tracts. As the disease becomes chronic, extensive scarring and fibrosis occurs. With the resultant pain, limitation of movement and offensive chronic discharge, the patients' quality of life can be severely compromised. The sexes are equally affected, although axillary disease is more common in women and anogenital disease in men. 3 There is often a past history of severe acne and many patients, especially women, are obese. 4 The most serious but rare long-term complication is of squamous cell carcinoma, mostly occurring in men in the anogenital area. The time interval between diagnosis of apocrine acne and appearance of squamous cell carcinoma is, on average 19 years. 5, 6 The pathogenesis of apocrine acne is still debated. The anatomical distribution suggests that the disease is a primary disorder of apocrine glands and it has been suggested that follicular occlusion is the primary event. This causes obstruction to apocrine secretion as the ducts of apocrine glands drain into the main follicle. Histological examination confirms ductal hypercornification and distension of apocrine glands with surrounding purulent inflammation. The observed association with other conditions in which follicular occlusion is a prominent feature (acne vulgaris, acne conglobata, dissecting cellulitis of the scalp and pilonidal sinus) supports this view. There is evidence that androgens may play a permissive role in the aetiology of apocrine acne. 9 Apocrine acne is associated with physiological endocrine events such as the onset of puberty, pregnancy and pre-menstrual exacerbations. It has been reported as a presenting feature of premature adrenarche in a 7.8-year-old girl. 10 Antiandrogen treatment has been used with modest success; however, a recent study by Barth et al. 11 found no supporting evidence of biochemical hyperandrogenism in women with apocrine acne.
Surgical removal of areas of burrowing inflammation offers a prompt solution to limited disease; however, more radical surgery may be needed for extensive disease. Indeed it has been suggested previously that only surgery offered a hope of a 'cure'. 4, 12, 13 Topical treatments including antiseptics, antibiotics and steroids are usually only of limited benefit. Apocrine acne shows a much less favourable response to systemic antibiotics than acne vulgaris. Anti-androgen treatment with cyproterone acetate in combination with ethinyloestradiol in women has been used with some success. 14, 15 Systemic steroids quell purulent inflammation and are of particular use in the acute stages.
The retinoid drugs which are so dramatically successful for sebaceous acne are less beneficial in this condition. This is probably because they are abandoned too soon; the inflammation is deeper and so more prolonged treatment is necessary. If successful, further treatment appears to be unecessary. [16] [17] [18] [19] Chow et al. have reported that etretinate and acitretin are more effective than isotretinoin in the treatment of apocrine acne. 20 There have been nine reported cases of successful treatment with acitretin and etretinate, five of which had been previously unresponsive to isotretinoin. 20, 21 The largest study by Stewart et al. involved six patients with apocrine acne who were treated with etretinate 0.35-1.1 mg/kg/day for up to 39 months. All patients demonstrated an excellent response after 12 months; however, relapse occurred 4 months after stopping the treatment. It was commented that no improvement was to be expected until at least 6 months after starting treatment. 17 The mechanisms of action of the retinoids in the treatment of apocrine acne may be multiple. Apocrine glands shrink with consequent reduction of secretions. Ductal hypercornification is reduced because of the influence on keratinization. An antineutrophil effect also occurs. 17, 22 The fact that some patients fail to respond to isotretinoin yet do so to etretinate and acitretin suggests that suppression of hyperkeratinization is more important than glandular shrinkage. However, in parous women a prolonged course of isotretinoin is probably a safer initial choice.
